Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Halozyme Therapeutics, Inc. (HALO) has a market cap of $7.97B with year-over-year revenue growth of +37.6%. Net margin stands at 22.7%. The stock trades at a P/E ratio of 25.2.
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, HALO posted revenue growth of +37.6% and trades at a P/E of 25.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.